A Phase II Trial of TAS-102 in Patients with Colorectal Cancer with Ctdna-Defined Minimal Residual Disease Post-Adjuvant Therapy: Results from the MD Anderson INTERCEPT Program.
JOURNAL OF CLINICAL ONCOLOGY（2024）
关键词
281-206-4760-6705,281-7668-514,283-237-255,130-2818,613-545-552,261-492-3532-2370-7650-2454,261-376-454,12
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要